1. Others
  2. Estrogen Receptor/ERR
  3. Erteberel

Erteberel (Synonyms: LY500307)

Cat. No.: HY-18295
Handling Instructions

Erteberel (LY500307) is a potent and selective estrogen receptor beta (ERβ) inhibitor with Ki and EC50 of 1.54 nM and 3.61 nM, respectively. Anti-tumor activities.

For research use only. We do not sell to patients.

Erteberel Chemical Structure

Erteberel Chemical Structure

CAS No. : 533884-09-2

Size Stock
250 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Technical Information

  • Purity & Documentation

  • References

Description

Erteberel (LY500307) is a potent and selective estrogen receptor beta (ERβ) inhibitor with Ki and EC50 of 1.54 nM and 3.61 nM, respectively[1]. Anti-tumor activities[2].

IC50 & Target

ERβ

1.54 nM (Ki)

ERβ

3.61 nM (EC50)

In Vitro

Treatment with Erteberel (0.25-10 μM, 72 hours) significantly reduces the proliferation of GBM cells with no activity on normal astrocytes in vitro[2].

Erteberel promotes apoptosis of GBM cells. Erteberel modulated several pathways related to apoptosis, cell cycle, and DNA damage response[2].

Erteberel (0-1000 μM) sensitizes GBM cells to several FDA-approved chemotherapeutic drugs including cisplatin, lomustine and temozolomide[2].

Cell Viability Assay[2]

Cell Line: U87, U251,T98G and normal astrocytes
Concentration: 0.25, 0.5, 1, 2, 4, 6, 8, and 10 μM
Incubation Time: 72 h
Result: Treatment with Erteberel significantly reduces the viability of various GBM cell lines in a dose-dependent manner. In contrast, viability of normal astrocytes is not affected at the tested doses, suggesting that Erteberel has tumor cell–specific activity[2].
In Vivo

Erteberel (5 mg/Kg body weight/day, oral, 28 days) treatment significantly reduces tumor growth and promotes apoptosis of GBM tumors in an orthotopic model[2].

Erteberel (5 mg/Kg body weight/day, oral, 40-50 days) treatment improves the overall survival of tumor-bearing mice in the GL26 syngeneic glioma model[2].

Animal Model: Athymic mice (5-7 weeks) inoculated with OVCAR-3 cells[2]
Dosage: 5mg/Kg body weight
Administration: Oral, daily for 28 days
Result: Immunohistochemical analysis reveals that Erteberel treatment significantly reduces the number of proliferation marker Ki-67-positive cells and increases the number of TUNEL-positive apoptotic cells[2].
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
Molecular Weight

282.33

Formula

C₁₈H₁₈O₃

CAS No.

533884-09-2

SMILES

OC1=CC=C2C([[email protected]@](CCC3)([H])[[email protected]@]3([H])[[email protected]](C4=CC=C(O)C=C4)O2)=C1

Shipping

Room temperature in continental US; may vary elsewhere

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Erteberel
Cat. No.:
HY-18295
Quantity:

Erteberel

Cat. No.: HY-18295